Biotech News
Related news
TNXPTonix Pharmaceuticals2026-11-04 12:00 EST
Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
NERVMinerva Neuroscience2026-10-29 11:00 EST
Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London
GANXGain Therapeutics2026-09-17 11:00 EST
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
TNXPTonix Pharmaceuticals2026-09-02 11:00 EST
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
HRMYHarmony Biosciences2026-08-27 12:05 EST
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
CGTXCognition Therapeutics2026-09-08 11:30 EST
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
NBIXNeurocrine Biosciences2026-09-02 20:01 EST
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
XENEXenon2026-11-03 21:01 EST
Xenon to Present at Upcoming Investor Conferences
ALKSAlkermes plc2026-11-03 21:00 EST
Alkermes to Present at Upcoming Investor Conferences
NBIXNeurocrine Biosciences2026-09-30 12:30 EST
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Xenon
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....
Recent company news
XENEXenon2026-11-03 21:01 EST
Xenon to Present at Upcoming Investor Conferences
XENEXenon2026-11-02 21:02 EST
Xenon to Report Q3 2026 Financial Results on November 9, 2026
XENEXenon2026-10-30 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
XENEXenon2026-10-29 12:30 EST
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
XENEXenon2026-10-02 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 37.68 USD
- Market cap
- 5.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States